Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156955 | 1.00 | GFPT1 (0.33) | GFPT1NOS3NOS1NOS2DPP4 | |
| SCHEMBL12278681 | 1.00 | GFPT1 (0.33) | GFPT1NOS3NOS1NOS2DPP4 | |
| SCHEMBL20198745 | 0.83 | SLC7A5 (0.31) | — | |
| SCHEMBL13242135 | 0.82 | BCAT2 (0.38) | GFPT1NOS3NOS1NOS2DPP4 | |
| SCHEMBL22122969 | 0.82 | GFPT1 (0.32) | GFPT1 | |
| SCHEMBL19371887 | 0.82 | GFPT1 (0.32) | GFPT1 | |
| SCHEMBL1527344 | 0.80 | GFPT1 (0.46) | GFPT1NOS3NOS1NOS2 | |
| SCHEMBL574087 | 0.80 | GFPT1 (0.46) | GFPT1NOS3NOS1NOS2 | |
| SCHEMBL393844 | 0.80 | GFPT1 (0.46) | GFPT1NOS3NOS1NOS2 | |
| SCHEMBL28387960 | 0.79 | KDM4E (0.39) | GFPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2021221656-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11077135-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | SYNEDGEN, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2897622-B1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION | SYNEDGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3311823-B1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020131283-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| EP-2555760-B1 | CHITOSAN DERIVATIVES FOR THE TREATMENT OF MUCOSITIS OR ULCERATION | SYNEDGEN INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180200286-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | UNITED STATES GOVERNMENT | 2018-07-19 | — | — | US | disclosed |
| EP-3311823-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | Synedgen, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180049965-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2018-02-22 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011127144-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | SYNEDGEN INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011028968-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028967-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | SYNEDGEN INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056896-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | UNITED STATES GOVERNMENT | 2010-03-04 | — | — | US | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | CHIT1, CHIA, ALG1 | GFPT1 1173/4885NOS3 775/4885NOS1 685/4885 |
| US-20180200286-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | CHIA, MMP8, CHIT1 | GFPT1 1664/4885NOS3 135/4885NOS1 320/4885 |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | NRDC, ARG1, CHIA | GFPT1 2363/4885NOS3 8/4885NOS1 20/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | GFPT1 664/4885NOS3 75/4885NOS1 83/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | GFPT1 1664/4885NOS3 135/4885NOS1 320/4885 |
| US-11077135-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | CHIA, CHI3L1, CHI3L2 | GFPT1 2018/4885NOS3 130/4885NOS1 561/4885 |
| US-20180049965-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | CHIT1, ALG1, SI | GFPT1 1444/4885NOS3 462/4885NOS1 481/4885 |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | CHIT1, CHIA, ALG1 | GFPT1 1294/4885NOS3 581/4885NOS1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.